Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Digital biomarkers
Continuous monitoring using digital biomarkers in MS care
- Benefits, limits and safety aspects
Phytotherapy for cardiovascular diseases
- Results of the FOREST HCM study
Symptomatic obstructive hypertrophic cardiomyopathy
- Neuroprotection, resilience and cognitive health in old age
Longevity & Brain
- Obesity as a chronic disease: an interdisciplinary perspective
Neurobiological mechanisms of obesity
- Oncolytic virus in stage II melanoma
Innovative method for predicting therapy response
- Phimosis and penile cancer under SGLT2i
Increased risk for men with T2D
- Diabetic ketoacidosis